Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-hr-10223119th CongressWALLET
End Tuberculosis Now Act of 2026
Sponsored By: Representative Bera, Ami [D-CA-6]
Introduced
Summary
end tuberculosis. This bill would direct U.S. foreign assistance to accelerate diagnosis, treatment, and prevention of tuberculosis worldwide. It would set timebound 2027–2030 targets and require annual, country-specific reporting and program evaluations.
Show full summary
- People with TB and at-risk groups would get expanded access to rapid molecular diagnostics, care for all TB forms including drug-resistant cases, patient support, and prophylaxis. The bill targets 90% diagnosis and treatment initiation and preventive treatment for 30 million people by 2030.
- Health systems, laboratories, and researchers would receive support for integrated molecular diagnostic networks, workforce training, procurement of quality TB commodities, and R&D on diagnostics, drugs, and vaccines.
- Partner countries and programs would be prioritized by TB burden and must report to the U.S. on screening, treatment initiation and completion, infection control, procurement, and co-investment. The statute requires an annual TB R&D report, a Comptroller General evaluation within four years, and a sunset on January 1, 2033.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More global help for tuberculosis
If enacted, the bill would let the President fund expanded TB programs worldwide. From January 1, 2027 to December 31, 2030 it would set numeric goals: cut TB cases 80% and TB deaths 90% from 2015 levels by 2030; diagnose and start treatment for 90% of TB cases and 90% of drug‑resistant cases; reach 90% treatment success; and provide preventive treatment to 30,000,000 people. The assistance would prioritize diagnosis, lab capacity, patient support, drug‑resistant TB care, research and development, and annual support for the Global Drug Facility. Grants and funding agreements would need access and affordability provisions. The authority and programs would remain in effect until January 1, 2033.
Sponsors & CoSponsors
Sponsor
Bera, Ami [D-CA-6]
CA • D
Cosponsors
Rep. Peters, Scott H. [D-CA-50]
CA • D
Sponsored 10/1/2026
Rep. Hayes, Jahana [D-CT-5]
CT • D
Sponsored 10/1/2026
Rep. Levin, Mike [D-CA-49]
CA • D
Sponsored 10/1/2026
Rep. Foushee, Valerie P. [D-NC-4]
NC • D
Sponsored 10/1/2026
Rep. Khanna, Ro [D-CA-17]
CA • D
Sponsored 10/1/2026
Rep. Stansbury, Melanie A. [D-NM-1]
NM • D
Sponsored 10/13/2026
Rep. Kelly, Robin L. [D-IL-2]
IL • D
Sponsored 10/13/2026
Rep. Watson Coleman, Bonnie [D-NJ-12]
NJ • D
Sponsored 10/13/2026
Rep. Crockett, Jasmine [D-TX-30]
TX • D
Sponsored 10/29/2026
Rep. Malliotakis, Nicole [R-NY-11]
NY • R
Sponsored 10/15/2026
Rep. Salazar, Maria Elvira [R-FL-27]
FL • R
Sponsored 9/2/2026
Rep. Doggett, Lloyd [D-TX-37]
TX • D
Sponsored 9/2/2026
Rep. Himes, James A. [D-CT-4]
CT • D
Sponsored 9/2/2026
Rep. Wilson, Joe [R-SC-2]
SC • R
Sponsored 9/2/2026
Rep. McCaul, Michael T. [R-TX-10]
TX • R
Sponsored 9/2/2026
Rep. Randall, Emily [D-WA-6]
WA • D
Sponsored 9/2/2026
Rep. Castro, Joaquin [D-TX-20]
TX • D
Sponsored 9/2/2026
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 9/2/2026
Rep. Ross, Deborah K. [D-NC-2]
NC • D
Sponsored 9/2/2026
Del. Radewagen, Aumua Amata Coleman [R-AS-At Large]
AS • R
Sponsored 9/15/2026
Rep. Tlaib, Rashida [D-MI-12]
MI • D
Sponsored 9/15/2026
Rep. Kean, Thomas H. [R-NJ-7]
NJ • R
Sponsored 9/15/2026
Rep. Davis, Donald G. [D-NC-1]
NC • D
Sponsored 9/15/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov